Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

United Therapeutics scraps development of esuberaprost after late-stage study failure in PAH

firstwordpharmaApril 09, 2019

Tag: United Therapeutics , esuberaprost , PAH

PharmaSources Customer Service